icon-folder.gif   Conference Reports for NATAP  
 
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
 
 
 
AASLD: Health Economics/Cost-Effectiveness
 
 
  Jules Levin, NATAP
 
Yesterday members of our NYS Hepatitis C Coalition including myself attended and testified at the NYS DURB hearing. Despite great testimony from 8 advocates NYS officials recommended to the committee that the F3/F4 restriction remain & the committee voted unanimously to approve, saying they would meet again after the Abbvie approval, clearly the decision comes from the very top NYS officials, the Governor's office I presume, and the state officials & the committee had decided in advance what the outcome would be, it was baked in the cake no matter what we said. However, apparently they did drop from the previously recommended criteria what we as a coalition requested them to drop - that HIV+ had to have undetectable HIV viral load - and - language "risk-based behavior" suggesting that treatment access could be used against drug users, whom by the way make up at least 50% of those HCV-infected in the USA.
 
Of note, NYS officials & the committee relied on earlier AASLD/IDSA/IAS-USA Guidance that F3/F4 should be prioritized & did not refer to new recently released Guidance rescinding this.
 
This report from California group holding hearing on Dec 18 reverses its opinion from earlier this year to this:
 
"results suggest that the introduction of LDV/SOF for both treatment-na´ve and treatment-experienced individuals would confer substantial clinical benefits in comparison to historical treatment standards and even in relation to other sofosbuvir-based regimens. While the use of this new regimen would increase treatment costs, such use appears to be cost-effective by conventional standards."
 
CTAF Report: Newest Treatments for Hepatitis C, Genotype 1: next public meeting of the California Technology Assessment Forum (CTAF) on Thursday, December 18, 2014 in Oakland, California. - (11/18/14)
 
Health Economics/Cost Effectiveness: AASLD: Projected Health and Economic Impact of Hepatitis C on the United States Medicare System From 2010 to 2024 - (11/17/14)
 
Health Economics/Cost Effectiveness: AASLD: LEDIPASVIR/SOFOSBUVIR SINGLE-TABLET REGIMEN FOR CHRONIC HEPATITS C (CHC) INFECTION: INSIGHTS FROM A WORK PRODUCTIVITY ECONOMIC MODEL - (11/17/14)
 
Health Economics/Cost Effectiveness: AASLD: Evaluation of the Health Outcomes for Ledipasvir / Sofosbuvir in Early vs. Delayed Treatment According to the Fibrosis Stage of Patients with Chronic Hepatitis C Virus (HCV) Genotype 1 Infection: Results from a Decision-Analytic Markov Model....... "initiating earlier LDV/SOF treatment at F0-2 vs F3/4 reduced liver disease progression/sequalae by 66-82% & rests in lower lifetime costs by 14.3-15.9%" - (11/17/14)
 
Health Economics/Cost Effectiveness: AASLD: Treatment with Interferon- and Ribavirin-Free Regimens with Ledipasvir and Sofosbuvir Improves Patient-Reported Outcomes for Patients with Genotype 1 Chronic Hepatitis C: Results from the ION-1, 2 and 3 Clinical Trials - (11/17/14)
 
Health Economics/Cost Effectiveness: AASLD: A Decision-Analytic Markov Model to Evaluate the Health Outcomes of Ledipasvir/Sofosbuvir for Patients with Chronic Hepatitis C Genotype 1 Infection - (11/17/14)
 
Health Economics/Cost Effectiveness: AASLD: Evaluation Of The Long-Term Health Outcomes Of Ledipasivir-Sofosbuvir (LDV/SOF) And Sofosbuvir-Based Regimens For Patients With Chronic Hepatitis C And Liver Cirrhosis Across Genotypes 1 To 4 - (11/17/14)
 
Health Economics/Cost Effectiveness: AASLD: Increased All-cause Hospitalization among Hepatitis C Virus Infected Persons: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010 - (11/17/14)
 
Health Economics/Cost Effectiveness: AASLD: Estimating the Number of Patients with Chronic Hepatitis C (HCV) Infection Meeting 'Highest' or 'High' Priority Treatment Criteria in the United States - (11/20/14)
 
Health Economics/Cost Effectiveness: AASLD:
Improving HCV care cascade outcomes in a community-based testing program by providing same day confirmatory testing and patient navigation - (11/20/14)
 
Health Economics/Cost Effectiveness: AASLD: FIB4 Score and Gender Predict the Incidence of Hepatocellular Carcinoma (HCC) among Patients with Chronic Hepatitis C Virus (HCV) Infection: Chronic Hepatitis Cohort Study (CHeCS) - (11/17/14)